Merck Teams Up With Sinopharm On Vaccines As It Gears Up For Gardasil Approval In China
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - U.S.-based Merck and China's Sinopharm plan to work together to develop vaccines in China under a preliminary deal that could ultimately see Sinopharm marketing more of the pharmaceutical giant's products in Asia's most populous nation
You may also be interested in...
Merck Ties Up With Zhifei To Distribute Gardasil In China, But What Happened To Sinopharm?
Merck has expanded its collaboration with Zhifei, its vaccine partner in China, by signing a three-year RMB 4.5 billion distribution deal for HPV vaccine Gardasil. But left unanswered is whether Merck will walk away from a partnership with Sinopharm it had previously emphasized.
Merck Ties Up With Zhifei To Distribute Gardasil In China, But What Happened To Sinopharm?
Merck has expanded its collaboration with Zhifei, its vaccine partner in China, by signing a three-year RMB 4.5 billion distribution deal for HPV vaccine Gardasil. But left unanswered is whether Merck will walk away from an intended partnership with Sinopharm it had previously emphasized.
Merck’s Emerging Markets R&D Head RuiPing Dong On Developing Drugs To Meet Local Needs: An Interview With PharmAsia News (Part 2 of 2)
Merck discusses its R&D strategy in emerging markets; the company announced last week the largest ever R&D investment in China for a pharmaceutical company.